Celularity Inc.
Celularity is a clinical and commercial stage biotechnology company focused on cellular and regenerative medicine, specializing in off-the-shelf placental-derived allogeneic cell therapies and biomaterial products aimed at addressing serious unmet medical needs.
Investor website: https://celularity.com/
We don’t have processed documents for Celularity Inc. yet, so the AI assistant isn’t available on this page.
About
Celularity is a clinical and commercial stage biotechnology company focused on cellular and regenerative medicine, specializing in off-the-shelf placental-derived allogeneic cell therapies and biomaterial products aimed at addressing serious unmet medical needs. The company believes in leveraging the unique biology of the placenta to create effective, accessible, and affordable therapeutics.
Verified company data
- Cash position
- $37.2 million
- Projects
- ["Advanced Biomaterials Pipeline\n\n| Advanced Biomaterials | Indication | Discovery | Regulatory | Commercialization |\n| --- | --- | --- | --- | --- |\n| **Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Ocular Protective Cover | <br>361 HCT/P |\n| **Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Placental Connective Tissue Matrix** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Celularity Tendon Wrap (CTW)** | Surgical Tendon Management | <br>Expected 510(k) filing |\n| **FUSE Bone Void**<br>**Filler** | Orthopedics / Bone, Spine, Dental | <br>Expected 510(k) filing |\n| **Celularity Placental Matrix (CPM)** | Soft Tissue Management | <br>Expected 510(k) filing |"]
- Leadership
- Robert J. Hariri, M.D., Ph.D. (Chairperson, Founder & CEO, Experienced leader in cellular and regenerative medicine with a focus on placental-derived therapies.), Andrew L. Pecora, M.D., F.A.C.P., C.P.E. (President, Renowned clinician and executive leader in biotechnology with over 25 years of experience in developing cellular medicines.), Anna Gosiewska, Ph.D. (R&D, Degenerative Diseases), Sharmila Koppisetti, M.D. (Clinical Development Immunology & Drug Safety), Tim Wilk (Technical Operations), Peter Diamandis, M.D. (Director), Geoffrey Shiu Fei Ling, M.D., Ph.D. (Director), Diane Parks (Director), Vincent LeVien (Director), Darren Sigal, M.D. (Co-Chairperson, Scientific Advisory Board), Louis Weiner, M.D. (Scientific Advisor)
Verified data last updated: